Mode
Text Size
Log in / Sign up

High-risk perfusion phenotypes correlate with early neurological deterioration and poor functional outcomes in low-NIHSS LVO strokeImaging markers help identify high risk in certain strokes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that high-risk perfusion phenotypes correlate with poor outcomes in low-NIHSS LVO stroke, but guided therapy evidence is uncertain.

This systematic review and exploratory meta-analysis evaluates perfusion and hemodynamic imaging markers, such as Tmax-defined hypoperfusion volumes and impaired hemodynamic reserve, in patients with large-vessel occlusion (LVO) stroke and low NIHSS scores. The analysis focuses on identifying high-risk tissue-at-risk phenotypes to inform clinical management.

The meta-analysis found that a high-risk perfusion phenotype was significantly associated with early neurological deterioration or deterioration of ischemic origin (OR 6.55; 95% CI, 1.65-25.99). Additionally, the high-risk perfusion phenotype was associated with poor functional outcomes (OR 9.24; 95% CI, 1.99-42.99). These findings suggest that specific imaging markers can identify patients at higher risk for clinical decline.

Despite these associations, the authors note that evidence regarding perfusion-guided endovascular therapy is heterogeneous and based on observational data. The clinical utility of using these markers to guide immediate decision-making remains uncertain. Randomized trials are required to establish whether perfusion-guided interventions provide a definitive benefit over standard care.

When someone suffers a stroke involving a large blood vessel, doctors must act quickly. For some patients who appear stable at first, it can be hard to predict if their condition will suddenly worsen. This study looked at how certain imaging markers—tools that measure blood flow and tissue health—could help identify these high-risk cases.

Researchers found that a specific group of imaging markers, known as a high-risk perfusion phenotype, was strongly linked to both sudden neurological decline and poorer long-term outcomes for patients with low initial severity scores. Essentially, these scans could highlight patients who might need closer monitoring or different care paths because their brain tissue is at greater risk.

While these imaging tools are useful for identifying risky patterns, the evidence is still early. Because much of the data comes from observational studies rather than controlled trials, it is not yet clear how these findings should change daily treatment decisions. More research is needed to confirm exactly how doctors can best use these scans to guide surgery or medicine.

What this means for you:
Specific blood flow markers can identify stroke patients at high risk for worsening symptoms and poorer outcomes.

Common questions

What does a high-risk perfusion phenotype mean?

A high-risk perfusion phenotype refers to a specific pattern of blood flow and tissue health seen on medical scans. In this study, these markers were strongly associated with both sudden neurological decline and poorer long-term functional outcomes for patients who initially appeared stable after a large vessel stroke.

Can these imaging tests help doctors decide on treatment?

While the imaging markers are good at identifying high-risk tissue, the evidence for using them to guide specific endovascular treatments is currently uncertain. Because the data is based on observational studies rather than randomized trials, doctors should consult with specialists regarding how these tools fit into a patient's care.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Patients with acute ischemic stroke due to large-vessel occlusion (LVO) may present with low National Institutes of Health Stroke Scale (NIHSS) scores, creating uncertainty regarding the need for endovascular therapy. Perfusion imaging may help identify patients at high risk for early neurological deterioration (END), but its clinical utility in this population remains unclear. METHODS: We performed a systematic review and exploratory meta-analysis of studies evaluating perfusion or hemodynamic imaging in adults with low-NIHSS LVO stroke. PubMed, Embase, Scopus, Web of Science, and the Cochrane Library were searched from inception to June 2026. Eligible studies reported associations between perfusion imaging markers and END or functional outcome, or evaluated imaging-informed endovascular decision-making. Random-effects models were used for exploratory pooled analyses. Risk of bias was assessed using QUIPS and ROBINS-I-informed domains, and certainty of evidence was evaluated using GRADE. RESULTS: The search identified 1698 records, of which 1372 remained after removal of duplicates. The evidence base included perfusion risk-stratification studies, endovascular decision-making studies, background reviews and meta-analyses, and ongoing trial protocols. Larger Tmax-defined hypoperfusion volumes, larger perfusion lesion volumes, and impaired hemodynamic reserve were associated with early neurological deterioration or poor functional outcome. In three studies eligible for exploratory pooling, a high-risk perfusion phenotype was associated with early neurological deterioration or deterioration of ischemic origin (pooled odds ratio, 6.55; 95% confidence interval, 1.65-25.99; I≈78%). Two studies suggested an association with poor functional outcome (pooled odds ratio, 9.24; 95% confidence interval, 1.99-42.99; I≈66%). Evidence regarding perfusion-guided endovascular therapy was heterogeneous and observational. CONCLUSIONS: In low-NIHSS LVO stroke, perfusion and hemodynamic imaging identifies a high-risk tissue-at-risk phenotype associated with neurological deterioration and poor outcome. However, evidence supporting perfusion-guided endovascular therapy remains uncertain. Randomized trials are required to define whether imaging-based selection improves outcomes in this population.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.